Compare Estee Lauder Companies Inc (EL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs TG Therapeutics Inc — how do they compare? Estee Lauder Companies Inc trades at $98.23 (market cap $34.17B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Estee Lauder Companies Inc is far larger — about 4.2× TG Therapeutics Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and TG Therapeutics Inc for 16 Days on average.
| EL | TGTX | |
|---|---|---|
Market Cap | $34.17B | $8.16B |
Volume | 3,921,497 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $59.06 |
52-Week Low | $67.23 | $26.94 |
Typical Hold Time | 122 Days | 16 Days |
Enterprise Value | $39.92B | $8.37B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $98.05, up 3.81% today, with a neutral technical signal and bullish moving averages. The stock has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $1.13 billion in 2025. Analyst consensus is a Buy with a $103.00 price target, and recent news highlights strategic partnerships in AI and leadership changes.
The outlook is mixed: strong gross margins and recent earnings beats support upside, but high valuation ratios and negative net income pose risks. Investor sentiment is cautiously optimistic, driven by digital initiatives and brand strategy, yet competitive pressures and macroeconomic headwinds remain key concerns for sustained growth.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
